Our Spinoff Companies
We are leading the way with proactive strategies and cutting-edge science to build a healthier global community through innovative solutions.
HKUBio is developing the Flu-based viral vector intranasal vaccine intranasal vaccine for influenza, COVID-19, and other future respiratory viral diseases.
(BiomOrgan)
BiomOrgan aims to provide cutting-edge organoid culture product development and various organoid-based services and disease model construction and applications to academia and industry using our exclusive patented respiratory organoid platform and expertise.
Hong Kong Universal Vaccine Limited
(HKUV)
HKUV dedicates to the development of a novel live attenuated vaccine platform to provide a safe and effective vaccine for various respiratory diseases
Orimmune BioTech Limited
(Orimmune)
Orimmune dedicates to the Research and development of the lead Δ42PD1 antibody drug as an immunotherapy against cancers and infections
Antenovus is dedicated to providing natural, sustainable, and non-antibiotic solutions for combating microbial infections and related diseases.